A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Public ClinicalTrials.gov record NCT03729245. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to compare the objective response rate (ORR) and overall survival (OS) of bempegaldesleukin (NKTR-214: BEMPEG) combined with nivolumab to that of tyrosine kinase inhibitor (TKI) monotherapy (sunitinib or cabozantinib) in IMDC intermediate- or poor-risk patients and IMDC all-risk patients with previously untreated advanced renal cell carcinoma (RCC).
Study identification
- NCT ID
- NCT03729245
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 623 participants
Conditions and interventions
Interventions
- bempegaldesleukin Biological
- sunitinib Drug
- nivolumab Biological
- cabozantinib Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2018 (Actual)
- Primary completion
- Jan 7, 2022 (Actual)
- Completion
- Oct 19, 2022 (Actual)
- Last update posted
- Apr 11, 2023
2018 – 2022
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Urological | Anchorage | Alaska | 99503 | — |
| Western Regional Medical Center - CTCA - PPDS | Goodyear | Arizona | 85338 | — |
| CARTI Cancer Center | Little Rock | Arkansas | 72205 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| University of California Irvine | Orange | California | 92868 | — |
| Innovative Clinical Research Institute | Whittier | California | 90603 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | — |
| Tulane Medical Center | New Orleans | Louisiana | 70112 | — |
| University of Maryland Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89106 | — |
| North Shore Hematology Oncology Association PC | Port Jefferson Station | New York | 11776 | — |
| Kettering Medical Center | Kettering | Ohio | 45429 | — |
| Providence Cancer Institute, Franz Clinic | Portland | Oregon | 97213 | — |
| Lehigh Valley Physician Group (LVPG) - Hematology Oncology | Allentown | Pennsylvania | 18103 | — |
| Penn State Milton S Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Eastern Regional Medical Center - CTCA | Philadelphia | Pennsylvania | 19124 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Huntsman Cancer Hospital - PPDS | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 76 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03729245, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 11, 2023 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03729245 live on ClinicalTrials.gov.